Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. BESPONSA (inotuzumab ozogamicine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

BESPONSA (inotuzumab ozogamicine)

Medicine - Posted on Oct 10 2022
Active substance (DCI)
  • inotuzumab ozogamicine
history (2)
  • 9/21/22

    BESPONSA (inotuzumab ozogamicine)

    Key points Approval of reimbursement only for the treatment of adult patients with relapsed or refractory Philadelphia chrom...
    CAV :
    54321
    icône flèche
  • 2/7/18

    BESPONSA (inotuzumab ozogamicin), antineoplastic monoclonal antibody

    For the treatment of relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukaemia, Philadelphia chrom...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XC26
Manufacturer
PFIZER PFE FRANCE
Presentation

BESPONSA 1 mg, poudre pour solution à diluer pour perfusion (code CIS : 61847017)
1 flacon(s) en verre brun de 1 mg - (Code CIP : 34009 550 334 7 9)

All our publications
    Congenital, genetic and rare diseases Drug therapy Hematologic cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
Lk2VSpG3gCjqVMAn